TP53 and acute myeloid leukemia: As detailed previously, the presence of a TP53 mutation confers an extremely poor prognosis even among AML patients who undergo allo-HCT, so it is hopeful that magrolimab’s promising activity in the newly diagnosed setting will translate to post-transplant, relapsed patients.